Your partner in drug discovery in inflammation and infection

Welcome to Artimmune - Your trusted partner in drug discovery for inflammation and infection. With a focus on scientific expertise, collaboration, and reliability, we are dedicated to advancing research in immunology and inflammation. As the world faces the challenges of COVID-19, Artimmune is committed to providing optimized research solutions. Our murine model of cytokine storm aids in the investigation of new drug candidates to combat COVID-19. Explore our preclinical CRO services and benefit from our extensive experience in lung diseases and immunology. Contact us to drive your research projects forward.

Your partner in successful preclinical projects in inflammation

Contact Us
Scientific expertise, Collaboration, Reliability

Contact Us
COVID-19 - While our priority is the health and safety of our staff, we operate thanks to an optimized organization and answer any request to run your research projects. > Contact us

The devastating pandemic of COVID-19 (coronavirus disease 2019) is dramatically affecting every country on Earth, with millions of deaths and global economy turndown. Much of the mortality has been associated with a cytokine storm syndrome in patients admitted to hospital with COVID-19 pneumonia.

At ARTIMMUNE, we propose a murine model of cytokine storm to better investigate the therapeutic effects of new drug candidates designed to improve the mortality rate due to COVID-19 infection. > More information

Preclinical CRO

  • Our CRO Company

    ArtImmune is a contract research company which offers consulting and preclinical research services in immunology and inflammation with an emphasis on lung diseases.
  • Our Preclinical Expertise

    ArtImmune has a strong expertise in preclinical investigations of lung functions in vivo including plethysmography, bronchoalveolar lavage, cytology, histology, immunohistochemistry, and analysis of biochemical, immunological and molecular parameters.
  • Our Immunology Mission

    To evaluate in vivo the effects of novel drug candidates in lung, skin and gut diseases : allergic asthma, chronic bronchitis, lung fibrosis, emphysema and acute respiratory distress syndrome, psoriasis, wound healing, atopic dermatitis, and inflammatory Bowel disease (IBD), Pseudomonas aeruginosa and influenza A virus infection.
  • Cro Preclinical Partnerships

    The company results from a partnership between Key-Obs and the laboratory of Immunology INEM - UMR7355 - CNRS (CNRS and University - Orleans France). This partnership has allowed to establish relevant experimental models of lung diseases which are proposed in an expert environment.